Skip to content

Nivolumab/Ipilimumab Could Be Most Efficient mRCC Therapy, Sunitinib Most Price-Efficient

Sunitinib (Sutent) was probably the most cost-effective immunotherapy remedy choice for sufferers with metastatic renal cell carcinoma (mRCC) in an evaluation of the drug and different authorized immunotherapy (IO)/IO-tyrosine kinase inhibitor (TKI) drug mixtures utilizing public payer acquisition prices in the USA. Notably, nivolumab (Opdivo) plus ipilimumab (Yervoy) was deemed the best remedy choice within the mannequin however didn’t meet the willingness-to-pay threshold (WTP).one

Sunitinib was ranked because the least costly remedy within the mannequin. Its prices had been estimated to be between $357,948 USD and $656,100 USD throughout a 10-year span. Lenvatinib (Lenvima) plus pembrolizumab (Keytruda) or pembrolizumab plus axitinib (Inlyta) had been ranked as the most costly (vary, $959,302 USD-$1,403,671 USD). Nivolumab plus ipilimumab garnered the best variety of quality-of-life years (QALYs; 3.6) and avelumab (Bavenzio) plus axitinib procured the least variety of QALYs (2.5).

“Our outcomes show that sunitinib was probably the most cost-effective first-line technique at a WTP of $150,000 USD/QALY, which is the brink sometimes utilized by the US Institute for Scientific and Financial Analysis due to decrease drug-associated prices in contrast with all different authorized IO-IO and IO-TKI mixtures,” wrote Minkyoung Yoo, PhD, of the College of Utah Well being Programs, and co-investigators, within the examine. “Amongst mixture therapies, [nivolumab plus ipilimumab] was the one technique not dominated by sunitinib. [Nivolumab plus ipilimumab] was related to greater QALYs over a 10-year time horizon vs all different choices together with sunitinib.”

In the USA, the estimated incidence of renal cell most cancers for 2022 was 79,000, leading to roughly 13,900 deaths. Vital advances have been made to deal with this illness, together with quite a few immunotherapies and IO-based drug mixtures, together with mixtures with TKIs. These remedies have demonstrated vital enhancements in response charges, progression-free survival (PFS), and general survival (OS). Nevertheless, it is very important notice the charges of immune-related adversarial occasions (irAEs), which may have an effect on general remedy prices and subsequently warrant monetary concerns. In 1 systematic overview of sufferers with urologic cancers who obtained immunotherapy or IO-TKI mixture remedy, the speed of any-grade treatment-related AEs was 88.3%, together with an any-grade irAE charge of 42.7%.2

Investigators designed a choice mannequin with a 10-year time horizon. They included 7 totally different remedy methods; these had been atezolizumab (Tecentriq) plus bevacizumab (Avastin); avelumab plus axitinib; pembrolizumab plus axitinib, nivolumab plus ipilimumab, nivolumab plus cabozantinib (Cometriq), lenvatinib plus pembrolizumab, and sunitinib alone. These remedies had been measured by way of QALYs with utility values, based mostly on the revealed literature. The prices embrace the drug acquisition prices together with the administration of grade 3 or 4 drug-related adversarial occasions.one

Examine authors famous that with a better willingness-to-pay threshold, nivolumab/ipilimumab could be probably the most cost-effective. These outcomes had been constant throughout the VA Federal Provide Schedule Service (VA FSS) and the Nationwide Common Drug Acquisition Price (NADAC) drug prices, and whether or not sufferers had been assumed to obtain second-line remedy after the failure of first-line remedy.

The mannequin included a partitioned survival mannequin, by which sufferers transitioned between 3 well being states, progression-free, progressive illness, and demise, at month-to-month intervals, on the fundamental of parametric survival operate. There have been estimated from revealed survival curves. Price-effectiveness was decided by incremental cost-effectiveness ratios (ICERs) by dividing the distinction in price by the distinction in effectiveness between nondenominated remedies.one

Whatever the perspective and the speed of subsequent remedy, sunitinib demonstrated the bottom 10-year whole prices at $467,394 USD to $726,068 USD (together with medicines, administration prices, and drug-related adversarial occasions), whereas lenvatinib/pembrolizumab or pembrolizumab/axitinib confirmed the best (vary, $1,116,302 USD-$1,502,129).one

The estimated 10-year QALYs ranged from 2.52 for avelumab/axitinib to three.60 years with nivolumab plus ipilimumab. Atezolizumab plus bevacizumab, avelumab plus axitinib, nivolumab plus cabozantinib, lenvatinib/pembrolizumab, and pembrolizumab/axitinib weren’t thought-about on this a part of the evaluation as a result of they had been each much less efficient and costlier than sunitinib alone, and nivolumab/ipilimumab, or a linear mixture of each remedies.one

The incremental cost-effectiveness ratio for nivolumab/ipilimumab, was from $297,465 USD per QALY in a mannequin the place 30% of sufferers had been receiving second-line remedy and the V FSS was used for pricing, to $422,220 USD/QALY in a model the place all sufferers had been Medicare/Medicaid beneficiaries and had been receiving second-line remedy.one

In response to examine authors, this examine differs from different publish cost-effective analyzes for mRCC, together with Shay et al, which deemed nivolumab/ipilimumab to be most cost-effective, however didn’t embrace sunitinib as a comparator.3 One key distinction with this examine is that it used the NADAC and VA FSS to find out drug costs, whereas many different revealed analyzes used the producers’ checklist value, which doesn’t embrace reductions and rebates. Moreover, this examine ran a model of the mannequin by which all sufferers obtained second-line remedy, as nicely a model by which solely 30% did, in addition they included a complete of all 7 first-line authorized remedies, slightly than a subset of therapies.one

The examine authors acknowledged that extrapolating survival information to a 10-year time horizon invitations uncertainty. Though they examined numerous potential parametric survival features, used 6 unbiased medical trials to match every IO-TKI mixture towards sunitinib, this uncertainty should be current. Moreover, the Kaplan-Meier PFS and OS curves for sunitinib range throughout every of those research. Consequently, investigators used each the best and lowest reported median PFS time from the 6 trials.

Lastly, though the VA FSSS and Common Gross sales Value/NADAC might characterize the precise medication prices higher than the wholesale acquisitions, examine authors acknowledge that drug costs nonetheless very significantly throughout payers in the USA—and the examine didn’t embrace out-of- pocket prices.

References

  1. Yoo M, Nelson RE, Cutshall Z, Dougherty M, Kohli M. Price-effectiveness evaluation of six immunotherapy-based regimens and sunitinib in metastatic renal cell carcinoma: a public payer perspective. JCO Oncol Pract. Printed on-line January 4, 2023. doi:10.1200/OP.22.00447
  2. Wu Z, Chen Q, Qu L, et al. Antagonistic occasions of immune checkpoint inhibitors remedy for urologic most cancers sufferers in medical trials: a collaborative systematic overview and meta-analysis. Eur Urol. 2022;81(4):414-425. doi:10.1016/j.eururo.2022.01.028
  3. Shay RC, Nicklawsky A, Lam ET. Comparative effectiveness of mixture first-line therapies for metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2021;39 (suppl 15):e16549. doi:10.1200/JCO.2021.39.15_suppl.e16549

.

Leave a Reply

Your email address will not be published. Required fields are marked *